Rare diseases
Investigational molecules
Locations
Route 206, Province Line Road, 08543, United States
Mirati Therapeutics Inc. focuses heavily on advanced non-small cell lung cancer with KRAS G12C mutation, including both non-squamous and broader lung cancer populations. Its studies examine treatment settings across first-line and previously treated disease, reflecting a strong emphasis on targeted approaches for lung tumours driven by this molecular alteration.
The sponsor also explores combinations with pembrolizumab and other systemic therapies in non-small cell lung cancer, highlighting a sustained interest in molecularly defined thoracic oncology.
Mirati Therapeutics Inc. runs clinical trials in conditions such as Non-small cell lung cancer, Colorectal cancer metastatic, Non-small cell lung cancer metastatic, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Austria
France
ItalyAustriaAustria
CroatiaIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
